The Lancet, an authoritative international medical journal, recently published a paper, introducing the positive results of the first phase clinical trial of COVID-19 candidate vaccine developed by China's team. They conducted a 1 clinical trial on a COVID-19 vaccine, and the results showed that the vaccine was safe and could induce a rapid immune response.
The vaccine used in the experiment is adenovirus vector recombinant COVID-19 vaccine. In the experiment, the research team recruited 108 healthy adult volunteers, aged between 18 and 60. These volunteers were divided into different groups and vaccinated with different doses of vaccine. According to the report, within 28 days after inoculation, the vaccine showed good tolerance in different dose groups and did not cause serious adverse reactions.
In the press release issued by The Lancet, Chen Wei said that clinical trials in phase 1 showed that recombinant COVID-19 vaccine using this adenovirus vector could induce virus-specific antibodies and T cells within 14 days, "these results represent an important milestone".
Extended data:
The phased results of vaccine research and development in COVID-19 have been well received by American and British scientists.
Robert Schooley, director of the Department of Infectious Diseases at the University of California, San Diego, told Xinhua that volunteers who were vaccinated with three different doses of candidate vaccines all produced neutralizing antibodies and T cell immune responses against COVID-19 and showed good tolerance; Within 28 days after inoculation, the neutralizing antibody in most people increased by more than 4 times, which is "encouraging".
Daniel altman, professor of immunology at Imperial College London in London, UK, said that this is the first paper to report the results of clinical trials of COVID-19 vaccine. The vaccine induced a neutralizing antibody reaction related to the inoculation dose, and the volunteers did not have serious adverse reactions, so it was a "good start" and the test results were "quite gratifying".
The results of the first phase clinical trial of People's Health Network-China COVID-19 vaccine are encouraging.